ALAMEDA, Calif., Nov. 7, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, 2017. Revenue of $83.9 million in the third quarter of 2017, an increase of 24.9%, or 24.1% in constant currency1, over the third quarter of 2016. […]
Tag: Penumbra
Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for fiscal 2018. Recent Highlights First Patient Enrolled in TRANSCEND Pivotal Clinical […]
Penumbra, Inc. Announces Participation at Upcoming Investor Conferences
ALAMEDA, Calif., Aug. 24, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event: Wells Fargo 2017 Healthcare Conference Location: Boston, MA at the Westin Boston Waterfront Date: Thursday, September 7, 2017 Time: 1:40pm ET / 10:40am PT Event: Morgan […]
Penumbra, Inc. Reports Second Quarter 2017 Financial Results
ALAMEDA, Calif., Aug. 8, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the second quarter ended June 30, 2017. Revenue of $80.6 million in the second quarter of 2017, an increase of 23.8%, or 24.6% in constant currency1, over the second quarter of 2016. […]
Penumbra Schedules Second Quarter 2017 Earnings Release And Conference Call For August 8, 2017 At 4:30 PM Eastern Time
ALAMEDA, Calif., July 25, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2017 after market close on Tuesday, August 8, 2017 at 4:30 PM Eastern Time. A press release with second quarter 2017 financial results will be issued after market close […]
Penumbra initiates recall of 3D Revascularation Device
Penumbra Inc. Recalls 3D Revascularization Device Due to Wire Material That May Break or Separate During Use Penumbra Inc. is recalling the Penumbra 3D Revascularization device because there is a risk of the delivery wire breaking or separating during use. Fractured pieces of the delivery wire could be left inside […]
Penumbra Promotes Daniel Davis To Chief Commercial Officer
ALAMEDA, Calif., July 5, 2017 /PRNewswire/ Penumbra, Inc. (NYSE: PEN) today announced that Daniel Davis has been promoted and will add the title of Chief Commercial Officer to his existing title of President, North America. Mr. Davis joined Penumbra in 2007 as one of the first members of the Company’s sales team and has advanced […]
Recent
Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Bunkerhill Health and Cleerly Announce Strategic Partnership to Advance Noninvasive Cardiovascular Care
Popular
- No commented posts yet